Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC).
Shiva ShrotriyaManoj Ponadka RaiAhmad AlratrootErin SarzynskiPublished in: BMJ case reports (2018)
We describe a 73-year-old man who developed adrenal insufficiency 7 months after completing nivolumab therapy for advanced non-small cell lung cancer. He presented with non-specific symptoms of malaise and fatigue with an insidious 13.6 kilogram weight loss, prompting an evaluation for disease progression, which was negative. Subsequent evaluation revealed isolated adrenocorticotropin insufficiency as the aetiology, attributed to a delayed side effect of nivolumab therapy.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- weight loss
- single cell
- bariatric surgery
- sleep quality
- small cell lung cancer
- cell therapy
- tyrosine kinase
- stem cells
- gastric bypass
- metabolic syndrome
- type diabetes
- adipose tissue
- bone marrow
- mesenchymal stem cells
- skeletal muscle
- insulin resistance